[go: up one dir, main page]

AR077316A2 - Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 - Google Patents

Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6

Info

Publication number
AR077316A2
AR077316A2 ARP100102573A ARP100102573A AR077316A2 AR 077316 A2 AR077316 A2 AR 077316A2 AR P100102573 A ARP100102573 A AR P100102573A AR P100102573 A ARP100102573 A AR P100102573A AR 077316 A2 AR077316 A2 AR 077316A2
Authority
AR
Argentina
Prior art keywords
alkyl
fluorinated
alkoxy
halogen
radical
Prior art date
Application number
ARP100102573A
Other languages
English (en)
Inventor
Wilfried Martin Braje
A Haupt
Sean Turner
U Lange
Karla Drescher
Liliane Unger
D Plata
Roland Grandel
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of AR077316A2 publication Critical patent/AR077316A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Métodos de preparacion, composiciones farmacéuticas y uso de los mismos. Reivindicacion 1: Un compuesto de la formula 1 caracterizado porque n es 0,1 o 2; G es CH2 o CHR3; R1 es H, alquilo C1-6, alquilo C1-6 sustituido por cicloalquilo C3-6, hidroxialquilo C1-6, alquilo fluorado C1-6, cicloalquilo C3-6, cicloalquilo fluorado C3-6, alquenilo C3-6, alquenilo fluorado C3-6, formilo, acetilo, propionilo o bencilo; R2, R3 y R4 son, en forma independiente entre sí, H, metilo, fluorometilo, difluorometilo, o trifluorometilo; A es 1,4-fenileno o 1,3-fenileno, que es opcionalmente sustituido por uno, dos, tres o cuatro sustituyentes seleccionados entre halogeno, alquilo C1-4, alcoxi C1-4, alquilo fluorado C1-4 y alcoxi fluorado C1-4; E es NR5 o CH2, en donde R5 es H o alquilo C1-3; Ar es un radical de la formula A, B, C, D, E, F o G en donde Ra es halogeno, hidroxilo, alquilo C1-6, alquilo fluorado C1-6, hidroxialquilo C1-6, alcoxi C1-6-alquilo C1-6, alquenilo C2-6, alquenilo fluorado C2-6, cicloalquilo C3-6, cicloalquilo fluorado C3-6, alcoxi C1-6, hidroxialcoxi C1-6, alcoxi C1-6-alcoxi C1-6, alcoxi C1-6 fluorado, alquiltio C1-6, alquiltio fluorado C1-6, alquilsulfinilo C1-6, alquilsulfinilo fluorado C1-6, alquilsulfonilo C1-6, alquilsulfonilo fluorado C1-6, fenilsulfonilo, piridilsulfonilo, benciloxi, fenoxi, fenilo, donde el fenilo y el radical piridilo en los ultimos 5 radicales pueden no estar sustituidos o pueden tener entre 1 y 3 sustituyentes seleccionados entre alquilo C1-4, alquilo fluorado C1-4 y halogeno, CN, nitro, alquilcarbonilo C1-6, alquilcarbonilo fluorado C1-6, alquilcarbonilamino C1-6, alquilcarbonilamino fluorado C1-6, carboxi, NH-C(O)-NR6R7, NR6R7, NR6R7-C1-6-alquileno, O-NR6R7, donde R6 y R7 son, en forma independiente entre sí, H, alquilo C1-4, alquilo fluorado C1-4 o alcoxi C1-4 o pueden formar, junto con N, un anillo saturado o insaturado de 4, 5, o 6 miembros, R9-CO-NR6-C1-6-alquileno, donde R6 tiene los valores que se han definido y R9 es alquilo C1-4 o fenilo, donde el radical fenilo puede no estar sustituido o puede tener entre 1 y 3 sustituyentes seleccionados entre alquilo C1-4, alquilo fluorado C1-4 y halogeno, CH2-piridilo, donde el radical piridilo puede no estar sustituido o puede tener entre 1 y 3 sustituyentes seleccionados entre alquilo C1-4, alquilo fluorado C1-4 y halogeno, o es un anillo heterocíclico saturado o insaturado, aromático o no aromático de 3 a 7 miembros que comprende como miembros del anillo 1, 2, 3 o 4 heteroátomos seleccionados entre N, O y S y/o 1, 2 o 3 grupos que contienen heteroátomos seleccionados entre NR8, donde R8 es H, alquilo C1-4, alquilo fluorado C1-4, alquilcarbonilo C1-4 o alquilcarbonilo fluorado C1-4, SO, SO2 y CO, y donde el heterociclo puede tener 1, 2 o 3 sustituyentes seleccionados entre hidroxi, halogeno, alquilo C1-6, alquilo fluorado C1-6, alcoxi C1-6, alcoxi fluorado C1-6, alquiltio C1-6, alquiltio fluorado C1-6, NR6R7-C1-6-alquileno, donde R6 y R7 tienen los valores que se han definido, carboxilo y alquiloxicarbonilo C1-4; Rb y Rc, en forma independiente entre sí, son H, halogeno, CH3, OCH3, CH2F, OCH2F, CHF2, OCHF2, CF3, OCF3, CH2CH2F, OCH2CH2F, CH2CHF2, OCH2CHF2, CH2CF3 o OCH2CF3; Rd se define como Ra; Re es H o se define como Ra; Rf se define como Ra; k es 0, 1, 2 o 3; y j es 0, 1, 2, 3 o 4; con la salvedad de que Ra no es F, CH2F, CHF2, CF3 o OCF3 si A es 1,4-fenileno, Ar es un radical de la formula (A) y Rb y Rc son H o halogeno; excepto los compuestos, donde R1 es propilo, G es CH2, n es 1, A es 1,4-fenileno, E es NH, Ar es un radical de formula (F) y Rd es halogeno, alquilo C1-6, alquenilo C2-6 o un atillo heteroaromático de 5 miembros; y sales de adicion ácida de los mismos toleradas fisiologicamente.
ARP100102573A 2006-04-19 2010-07-15 Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 AR077316A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79313906P 2006-04-19 2006-04-19

Publications (1)

Publication Number Publication Date
AR077316A2 true AR077316A2 (es) 2011-08-17

Family

ID=38231700

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070101658A AR060526A1 (es) 2006-04-19 2007-04-18 Compuestos heterociclicos para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6
ARP100102573A AR077316A2 (es) 2006-04-19 2010-07-15 Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP070101658A AR060526A1 (es) 2006-04-19 2007-04-18 Compuestos heterociclicos para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6

Country Status (19)

Country Link
US (1) US8642642B2 (es)
EP (1) EP2029528A1 (es)
JP (1) JP2009534354A (es)
KR (1) KR20080112394A (es)
CN (1) CN101421234A (es)
AR (2) AR060526A1 (es)
AU (1) AU2007239494A1 (es)
BR (1) BRPI0710177A2 (es)
CA (1) CA2648891A1 (es)
CR (1) CR10371A (es)
DO (1) DOP2007000077A (es)
EC (1) ECSP088826A (es)
MX (1) MX2008013434A (es)
NZ (1) NZ572761A (es)
PE (1) PE20080191A1 (es)
RU (1) RU2451012C2 (es)
TW (1) TW200812961A (es)
UY (1) UY30295A1 (es)
WO (1) WO2007118899A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ555123A (en) * 2004-10-14 2011-01-28 Abbott Gmbh & Co Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
ATE495153T1 (de) * 2006-11-09 2011-01-15 Hoffmann La Roche Arylsulfonylpyrrolidine als 5-ht6-inhibitoren
WO2009109042A1 (en) * 2008-03-06 2009-09-11 Horbay Roger P A system, method and computer program for retention and optimization of gaming revenue and amelioration of negative gaming behaviour
KR20120016639A (ko) * 2009-04-30 2012-02-24 애보트 게엠베하 운트 콤파니 카게 세로토닌 5-ｈｔ6 수용체의 조절에 반응하는 장애를 치료하는 데 적합한 ｎ-페닐-(피페라지닐 또는 호모피페라지닐)-벤젠설폰아미드 또는 벤젠설포닐-페닐-(피페라진 또는 호모피페라진) 화합물
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
PL395470A1 (pl) * 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego
CN106902112B (zh) * 2017-03-07 2019-06-04 中国医学科学院医药生物技术研究所 Imb-a6作为雄激素受体拮抗剂的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7513494A (en) 1993-08-06 1995-02-28 Upjohn Company, The 2-aminoindans as selective dopamine d3 ligands
DK0807101T3 (da) 1995-02-01 2001-09-10 Upjohn Co 2-Aminoindaner som selektive dopamin-D3-ligander
US5646180A (en) * 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
ES2192677T3 (es) 1996-05-30 2003-10-16 Baker Hughes Inc Control de la corrosion por el acido naptenico con compuestos de tiofosforo.
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
TW450954B (en) 1998-05-14 2001-08-21 Pharmacia & Amp Upjohn Company Phenylsulfonamide-phenylethylamines useful as dopamine receptors
BR9912299A (pt) 1998-07-20 2001-11-20 Merck Patent Gmbh Derivados de bifenila
US20040127502A1 (en) * 2001-01-31 2004-07-01 Synaptic Pharmaceutical Corporation Use of GAL3 antagonist for treatment of depression
WO2002083863A2 (en) * 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
EP1406884A1 (en) * 2001-05-11 2004-04-14 Biovitrum Ab Arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
GB0321473D0 (en) 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
WO2005037830A1 (en) 2003-10-10 2005-04-28 Wyeth Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands
GB0411421D0 (en) 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
NZ555123A (en) * 2004-10-14 2011-01-28 Abbott Gmbh & Co Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
KR100909318B1 (ko) 2004-12-16 2009-07-24 에프. 호프만-라 로슈 아게 항비만제로서 피페라지닐 피리딘 유도체
US20080300259A1 (en) * 2005-02-23 2008-12-04 Hauske James R Multimediator 5-Ht6 Receptor Antagonists, and Uses Related Thereto
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
US8497273B2 (en) * 2006-04-19 2013-07-30 Abbott Gmbh & Co. Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor

Also Published As

Publication number Publication date
US8642642B2 (en) 2014-02-04
DOP2007000077A (es) 2008-01-15
PE20080191A1 (es) 2008-03-10
EP2029528A1 (en) 2009-03-04
KR20080112394A (ko) 2008-12-24
US20090306175A1 (en) 2009-12-10
CN101421234A (zh) 2009-04-29
CR10371A (es) 2008-12-11
NZ572761A (en) 2011-09-30
WO2007118899A1 (en) 2007-10-25
RU2008145597A (ru) 2010-05-27
ECSP088826A (es) 2008-11-27
CA2648891A1 (en) 2007-10-25
TW200812961A (en) 2008-03-16
AR060526A1 (es) 2008-06-25
AU2007239494A1 (en) 2007-10-25
JP2009534354A (ja) 2009-09-24
MX2008013434A (es) 2009-01-26
UY30295A1 (es) 2007-11-30
RU2451012C2 (ru) 2012-05-20
BRPI0710177A2 (pt) 2012-05-29

Similar Documents

Publication Publication Date Title
AR077316A2 (es) Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
PE20080970A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos
AR072791A1 (es) DERIVADOS DE TIAZOLIDIN-2, 4-DIONA, MÉTODOS PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA ELABORACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER.
ECSP10010693A (es) Compuestos pirazólicos 436
CU24100B1 (es) Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR066095A1 (es) Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla
GT200900280A (es) Derivados de 2 piridin carboxamida como moduladores de los canales de sodio
AR058703A1 (es) Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer
ECSP045253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
AR056511A1 (es) Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4
AR055916A1 (es) Derivados de dihidrobenzofurano, usos de los mismos en la preparacion de un medicamento y composicion farmaceutica
AR054320A1 (es) Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticas
AR078786A1 (es) Derivados de la cromenona
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
MX383762B (es) Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida.
CL2011001413A1 (es) Compuestos derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para la prevencion o el tratamiento de una infeccion bacteriana.
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
BR0313377A (pt) Bifenilcarnboxamidas substituìdas por n-aril piperidina como inibidores de secreção de apolipoproteìna b
PE20141527A1 (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, preparacion de los mismos y su uso terapeutico de los mismos
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
AR069781A1 (es) Compuestos de n-(2,3-dihidro-inden-2-il) propanosulfonamida, composicion farmaceutica que los comprenden y su uso para el tratamiento de la ezquizofrenia.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal